Director at Adaptive Biotechnologies (NASDAQ: ADPT) exercises options and sells shares

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an exercise-and-sale transaction in company stock. On June 25, 2026, she exercised stock options to acquire 52,084 shares of Common Stock at an exercise price of $7.80 per share, then sold 52,084 shares in an open-market transaction at a weighted-average price of $20.18 per share.

The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating they were scheduled in advance. Following the transactions, Griffin directly held 15,625 shares of Adaptive Biotechnologies Common Stock.

Insights

Equity compensation and insider-trading analyst

Director executes pre-planned option exercise and same-day share sale, a routine liquidity event.

Director Michelle Renee Griffin exercised options for 52,084 shares of Adaptive Biotechnologies Common Stock at an exercise price of $7.80 per share, then sold the same number of shares at a weighted-average price of $20.18. This is a classic exercise-and-sell pattern converting a derivative award into cash.

The filing states these trades were effected under a Rule 10b5-1 trading plan adopted on November 7, 2025, suggesting the timing was pre-scheduled rather than opportunistic. After these transactions, Griffin’s direct holdings stood at 15,625 shares, indicating she retains a smaller equity stake but has fully exercised this particular option grant.

Insider Trade Summary 10b5-1

Net Seller: 52,084 shares ($1,051,055)

Net Sell 3 txns

Insider GRIFFIN MICHELLE RENEE

Role null

Sold 52,084 shs ($1.05M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	52,084	$0.00	--
Exercise	Common Stock	52,084	$7.80	$406K
Sale	Common Stock	52,084	$20.18	$1.05M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 67,709 shares (Direct, null)

Footnotes (1)

1. The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option was fully vested and exercisable.

Key Figures

Shares sold: 52,084 shares Sale price: $20.18 per share Exercise price: $7.80 per share +3 more

6 metrics

Shares sold 52,084 shares Common Stock sold in open-market transaction at weighted-average price

Sale price $20.18 per share Weighted-average sale price for 52,084 shares on June 25, 2026

Exercise price $7.80 per share Stock option exercise price for 52,084 underlying shares

Shares exercised 52,084 shares Common Stock acquired through option exercise on June 25, 2026

Shares held after 15,625 shares Director’s direct Common Stock holdings following the reported transactions

Net share change -52,084 shares Net buy/sell direction for reported transactions (net-sell)

Key Terms

Rule 10b5-1 trading plan, weighted-average price, Stock Option (right to buy), open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported for this transaction is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 07:50 PM Accepted by SEC EDGAR 06/29/2026 - 07:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRIFFIN MICHELLE RENEE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		M(1)		52,084	A	$7.8	67,709	D
Common Stock	06/25/2026		S(1)		52,084	D	$20.18(2)	15,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.8	06/25/2026		M(1)			52,084	(3)	04/23/2029	Common Stock	52,084	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The option was fully vested and exercisable.

	/s/ Michelle Renee Griffin by Kyle Piskel, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ADPT director Michelle Renee Griffin report?

Michelle Renee Griffin reported exercising options for 52,084 Adaptive Biotechnologies shares at $7.80 and selling 52,084 shares at a weighted-average $20.18. This combined exercise-and-sale converted her stock option award into cash while leaving her with a smaller remaining common stock position.

At what prices did the ADPT director’s June 25, 2026 transactions occur?

On June 25, 2026, Griffin exercised stock options at an exercise price of $7.80 per share and sold 52,084 shares at a weighted-average $20.18. The sale occurred through multiple trades in a price range between $20.00 and $20.55, according to the filing disclosure.

How many Adaptive Biotechnologies shares does the director hold after this Form 4?

Following the June 25, 2026 transactions, Michelle Renee Griffin directly held 15,625 shares of Adaptive Biotechnologies Common Stock. The exercised option covering 52,084 shares was fully vested and, after exercise and sale, showed zero remaining derivative position in this particular grant.

Was the ADPT director’s stock sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 7, 2025. Such pre-arranged plans schedule trades in advance, which can reduce the significance of transaction timing as a signal of the insider’s short-term market view.

What type of derivative security did the ADPT director exercise?

Griffin exercised a stock option described as a "Stock Option (right to buy)" with a conversion or exercise price of $7.80 per share, covering 52,084 underlying Common Stock shares. After this exercise, the option position shown in the filing had zero remaining derivative shares outstanding.